These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23299791)

  • 1. Phase I dose-escalation study of oral vinflunine administered once daily for 6 weeks every 8 weeks in patients with advanced/metastatic solid tumours.
    Delord JP; Tourani JM; Lefresne F; Pétain A; Pouget JC; Ravaud A
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):647-56. PubMed ID: 23299791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors.
    Calvo E; Vermorken JB; Hiret S; Rodon J; Cortes J; Senellart H; Van den Brande J; Dyck J; Pétain A; Ferre P; Bennouna J
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1467-75. PubMed ID: 22382883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
    Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of IV vinflunine in combination with carboplatin in chemonaive patients with advanced non-small cell lung cancer.
    Tournoux-Facon C; Robinet G; Pinel MC; Ferre P; Tourani JM
    Am J Clin Oncol; 2012 Aug; 35(4):378-85. PubMed ID: 22814308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
    Lockhart AC; Bukowski R; Rothenberg ML; Wang KK; Cooper W; Grover J; Appleman L; Mayer PR; Shapiro M; Zhu AX
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):203-9. PubMed ID: 17091249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
    Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
    Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of pomalidomide given for patients with advanced solid tumors.
    Cooney MM; Nock C; Bokar J; Krishnamurthi S; Gibbons J; Rodal MB; Ness A; Remick SC; Dreicer R; Dowlati A
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):755-61. PubMed ID: 22875080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.
    Rosen LS; Senzer N; Mekhail T; Ganapathi R; Chai F; Savage RE; Waghorne C; Abbadessa G; Schwartz B; Dreicer R
    Clin Cancer Res; 2011 Dec; 17(24):7754-64. PubMed ID: 21976535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer.
    Chan S; Campone M; Santoro A; Conte PF; Bostnavaron M; Nguyen L
    Cancer Chemother Pharmacol; 2014 May; 73(5):903-10. PubMed ID: 24627219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of pazopanib in patients with advanced cancer.
    Hurwitz HI; Dowlati A; Saini S; Savage S; Suttle AB; Gibson DM; Hodge JP; Merkle EM; Pandite L
    Clin Cancer Res; 2009 Jun; 15(12):4220-7. PubMed ID: 19509175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study.
    Delva R; Pienkowski T; Tubiana N; Vanhoefer U; Longerey B; Douville I
    Cancer Chemother Pharmacol; 2007 May; 59(6):703-9. PubMed ID: 17021821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
    Soepenberg O; de Jonge MJ; Sparreboom A; de Bruin P; Eskens FA; de Heus G; Wanders J; Cheverton P; Ducharme MP; Verweij J
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):703-11. PubMed ID: 15701859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer.
    Zaman K; Durando X; Baurain JF; Humblet Y; Mazzeo F; Bostnavaron M; Meheust N; Monnoyer-Favrel S; Machiels JP; Bauer J
    Breast Cancer Res Treat; 2011 Jun; 127(3):689-96. PubMed ID: 21442199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of metronomic oral vinorelbine in patients with advanced cancer.
    Rajdev L; Negassa A; Dai Q; Goldberg G; Miller K; Sparano JA
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1119-24. PubMed ID: 21373895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
    Flaherty KT; Lorusso PM; Demichele A; Abramson VG; Courtney R; Randolph SS; Shaik MN; Wilner KD; O'Dwyer PJ; Schwartz GK
    Clin Cancer Res; 2012 Jan; 18(2):568-76. PubMed ID: 22090362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
    Ebbinghaus S; Rubin E; Hersh E; Cranmer LD; Bonate PL; Fram RJ; Jekunen A; Weitman S; Hammond LA
    Clin Cancer Res; 2005 Nov; 11(21):7807-16. PubMed ID: 16278403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.